RBC Capital analyst Luca Issi downgrades Sangamo Therapeutics (NASDAQ:SGMO) from Outperform to Sector Perform and lowers the price target from $6 to $2.
RBC Capital Downgrades Sangamo Therapeutics to Sector Perform, Lowers Price Target to $2
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.